Pancreatic Cancer Research

ResearcherOspedale San PaoloNo recent work listed

Roberto Labianca

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0001-7149-822X; OpenAlex author ID A5084773667. Sources: OpenAlex.

Their work

Papers
10 (first author 0, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
71
Papers, trials and grants by year

2012: 2 papers · 2013: none · 2014: 2 papers · 2015: 2 papers · 2016: none · 2017: 2 papers · 2018: 1 paper · 2019: none · 2020: none · 2021: 1 paper

Papers 10

  1. Nab-paclitaxel/gemcitabine combination is more effective than gemcitabine alone in locally advanced, unresectable pancreatic cancer - A GISCAD phase II randomi… Co-author DOI 10.1016/j.ejca.2021.02.023↗
  2. Consensus statement on mandatory measurements in pancreatic cancer trials (COMM-PACT) for systemic treatment of unresectable disease. Co-author DOI 10.1016/s1470-2045(18)30098-6↗
  3. Borderline resectable pancreatic cancer: More than an anatomical concept. Co-author DOI 10.1016/j.dld.2016.11.010↗
  4. Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer: A systematic review. Co-author DOI 10.1016/j.ejca.2017.05.025↗
  5. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Co-author DOI 10.1016/j.pan.2014.10.001↗
  6. The value of lactate dehydrogenase serum levels as a prognostic and predictive factor for advanced pancreatic cancer patients receiving sorafenib. Co-author DOI 10.18632/oncotarget.5197↗
  7. Sorafenib does not improve efficacy of chemotherapy in advanced pancreatic cancer: A GISCAD randomized phase II study. Co-author DOI 10.1016/j.dld.2013.09.020↗
  8. Guidelines for time-to-event end-point definitions in trials for pancreatic cancer. Results of the DATECAN initiative (Definition for the Assessment of Time-to… Co-author DOI 10.1016/j.ejca.2014.07.011↗
  9. FOLFIRI as second-line chemotherapy for advanced pancreatic cancer: a GISCAD multicenter phase II study. Last author DOI 10.1007/s00280-012-1875-1↗
  10. Treatment of advanced pancreatic cancer. Co-author DOI 10.1093/annonc/mds355↗

Closest collaborators

The 25 strongest of 71 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Stefano Cascinu · 6 shared papers, 2012–2021 · strength 0.32
  2. Sandro Barni · 5 shared papers, 2012–2017 · strength 0.25
  3. Stefania Mosconi · 4 shared papers, 2012–2021 · strength 0.22
  4. Rossana Berardi · 3 shared papers, 2014–2021 · strength 0.17
  5. Alberto Zaniboni · 3 shared papers, 2012–2021 · strength 0.16
  6. Fausto Petrelli · 2 shared papers, 2017 · strength 0.15
  7. Alessandro Bittoni · 2 shared papers, 2015–2021 · strength 0.13
  8. John P. Neoptolemos · 3 shared papers, 2014–2018 · strength 0.13
  9. Michele Reni · 2 shared papers, 2017–2018 · strength 0.13
  10. Jean‐Luc Van Laethem · 2 shared papers, 2015–2018 · strength 0.10
  11. Andrea Spallanzani · 1 shared paper, 2021 · strength 0.09
  12. Luigi Cavanna · 1 shared paper, 2021 · strength 0.09
  13. Francesco Perrone · 1 shared paper, 2021 · strength 0.09
  14. Roberto Bianco · 1 shared paper, 2021 · strength 0.09
  15. Franck Bonnetain · 2 shared papers, 2014–2018 · strength 0.08
  16. Thierry Conroy · 2 shared papers, 2014–2018 · strength 0.08
  17. Bengt L. G. Glimelius · 2 shared papers, 2014–2018 · strength 0.08
  18. Teresa Mercade Macarulla · 2 shared papers, 2014–2018 · strength 0.08
  19. Gianluca Tomasello · 1 shared paper, 2017 · strength 0.08
  20. Massimo Falconi · 1 shared paper, 2017 · strength 0.07
  21. Luca Faloppi · 2 shared papers, 2014–2015 · strength 0.07
  22. Michela Cinquini · 2 shared papers, 2014–2015 · strength 0.07
  23. Werner Scheithauer · 1 shared paper, 2018 · strength 0.05
  24. Richard Herrmann · 1 shared paper, 2018 · strength 0.05
  25. Helmut Frieß · 1 shared paper, 2018 · strength 0.05

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.